Takeda China Hosts Digital Health Innovation Conference to Build a Comprehensive Exchange Platform and Industry Ecosystem for China's Digital Healthcare

Hangzhou, China, November 24, 2023 — Recently, Takeda China co-organized one of the key matchmaking events of the Global Digital Trade Expo (hereinafter referred to as "Digital Trade Expo") held in Hangzhou — the 2023 Digital Healthcare Industry Conference. At the conference, Takeda China, along with its partners, released the "Digital Healthcare Practices and Experience Insights Report," which provided an in-depth analysis of the current state and future trends of digital healthcare, offering reference standards and models for the industry. Meanwhile, as one of the executing organizations of this year’s Digital Healthcare Industry Conference, Takeda China hosted the "Data Aggregation, Innovation for the Future" Digital Healthcare Innovation Conference. During the event, Takeda announced the further expansion of the partner lineup for its innovative incubation platform, TakedaSpark, aiming to promote advancements in digital healthcare by pooling more resources to benefit more patients. Numerous industry experts, partners, and scholars attended the conference to discuss the current state and development opportunities in digital healthcare.

Takeda China Digital Healthcare Innovation Conference Focuses on Digital Healthcare Innovation, Aiming to Build a Comprehensive Communication Platform and Industrial Community for China's Digital Healthcare. "This innovation conference is aimed at partners across the entire digital healthcare industry chain in China, jointly exploring the deep integration of digital technology and healthcare, and promoting the development of patient-centered innovative solutions," said George Shan, Global Senior Vice President of Takeda and President of Takeda China. "As an industry pioneer, Takeda is committed to promoting the establishment of new standards in the digital healthcare sector. We hope to collaborate with all sectors to explore development paths, drive high-quality industry growth, thereby accelerating the benefits for Chinese patients from the development of digital healthcare and contributing to 'Healthy China.'"

Speech by Mr. Dan Guohong, Senior Vice President of Takeda Pharmaceutical Company Limited and President of Takeda China

Driven by a series of policies and the joint efforts of the government, industry, academia, research, and investment sectors, digital technology has become a key driving force in reshaping and transforming the pharmaceuticals industry. At the same time, digital healthcare urgently needs to establish industry consensus and standards to further lay the foundation for high-quality development. The Digital Trade Expo is China's only national, international, and professional exhibition themed around digital trade, serving as a platform for discussing new standards, topics, and trends in international digital trade. As an important对接event of the Digital Trade Expo, the convening of the Digital Healthcare Industry Conference aims to promote high-level exchanges within the industry and build a highland for the life sciences and healthcare industry.

Takeda China, as a leader in digital healthcare, has deep accumulation and rich practice in the field of digital health. At this year's Digital Healthcare Industry Conference, Takeda China, together with its partners, released the "Digital Healthcare Practices and Insights Report," which encapsulates Takeda’s years of experience and cutting-edge insights in the digital domain. The report outlines the significance of digital health, innovative technological practices, and the vibrant status of China's digital health industry, while also providing a forward-looking view of the industry’s future. The release of the "Digital Healthcare Practices and Insights Report" not only offers valuable knowledge resources and practical guidelines for healthcare professionals but also provides profound insights into industry development for policymakers, research institutions, and investors alike.

Release Ceremony of "Insights Report on Digital Healthcare Practices and Experiences"

In this regard, Guohong Shan emphasized that Takeda is willing to share its years of experience in digital healthcare with peers from all sectors to promote medical progress, which is Takeda's commitment to patients and society. He said, "Takeda China adheres to the needs of patients, actively seeks cooperation with all sectors of society, and strengthens innovation through diversified cooperation models. We hope to use this Digital Healthcare Innovation Conference to jointly explore and optimize the environment for the development of digital healthcare to better serve patients."

At the Digital Healthcare Innovation Conference hosted by Takeda, the partner lineup of TakedaSpark, Takeda's innovation incubation platform, has once again advanced. Partnerships have been signed with Accenture, Amazon Web Services, PwC, and Shanghai BioPharm Innovation & Translation Fund, marking the official start of a new chapter of Group 5 (G5) collaboration and further diversifying the partners in Takeda's innovation ecosystem. Currently, the G5 partner lineup already covers various fields such as digital technology, professional consulting, and commercial implementation. In the future, it will continue to support the construction of an industry cooperation model that spans the entire cycle from incubation to commercialization in the digital healthcare sector, exploring the deep integration of digital technology and healthcare, patient-centered innovative solutions, and commercialization pathways.

TakedaSpark G5 Partner Launch Ceremony

Launched in 2021, TakedaSpark is Takeda China's influential open innovation incubation platform, focusing on three major areas: digital therapeutics, early screening and diagnosis, and intelligent services. To date, TakedaSpark has attracted over 200 local startups to participate, with 12 innovative solutions advancing to the final validation pilot collaboration stage, providing high-quality innovative medical services to patients and healthcare professionals.

Gu Qing, Head of Takeda China's Digital Technology Team, believes that the expansion of TakedaSpark partners sends a clear and positive signal — to benefit more patients, Takeda’s steps toward digital transformation are firm, and its attitude toward collaboration is open. He said, "We are exploring new models of cooperation and co-creation with innovative ecosystem partners to jointly build a digital innovation ecosystem. We hope to gather more professional insights and experiences to promote the implementation of digital healthcare achievements, further benefiting more patients."

This Digital Healthcare Innovation Conference invited relevant government leaders, well-known experts from top-tier tertiary hospitals, experts from renowned universities in China, heavyweight industry partners, and guests from all walks of life. Focusing on the frontier of digital healthcare innovation, the conference gathered professional insights covering the entire industrial chain from “government, industry, academia, research, and investment,” discussing the present and future of digital healthcare innovation.

Representative guests from government departments shared policies, introducing the development situation and contemporary missions of China's digital healthcare to the participants, and expressing their determination to continue supporting high-quality development in the medical and health sectors. Invited guests from related industrial chains also delivered keynote speeches on the industry scale and market transformation of digital healthcare, as well as the application of digital science in early disease screening, intelligent diagnosis and treatment, people-oriented services, and the integration of medical engineering, bringing the most cutting-edge discoveries.

Through the platform of the Digital Healthcare Innovation Conference, experts from all fields and industry partners gathered to share their experiences and gained more information and support from government leaders and academic experts. As an opportunity for exchange, the conference broke down information barriers, making communication across the entire industry chain possible.

China's biopharmaceutical industry is undergoing a transformation driven by "innovation," and in the future, China has the opportunity to become a global source of innovation. Having been in China for nearly 30 years, Takeda has rooted itself in the fertile ground of China's high-quality market development, fully leveraging the increasingly open market environment to build an integrated, innovative, and valuable digital healthcare ecosystem.

With the convening of this Digital Healthcare Innovation Conference, Takeda China's Digital Healthcare Innovation Conference and TakedaSpark have jointly become the external "business cards" of Takeda China's digital strategy. They are pushing Takeda China's digital strategy to new heights, focusing on the deep integration of digital technology and healthcare for partners across the entire digital healthcare industry chain in China. Adhering to the patient-centric philosophy and with an open attitude, they leverage synergistic strengths, aiming to establish industry standards in digital healthcare and jointly promote high-quality development in China’s pharmaceuticals industry.

Takeda Pharmaceutical Company Limited is guided by the mission of "creating a healthier life for humanity and building a better future for the world." We focus on key therapeutic areas such as gastroenterology and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines, striving to develop and deliver groundbreaking innovative treatments to patients. Our goal is to collaborate with partners, leveraging our dynamic and diverse pipeline, to continuously enhance patient experiences and expand the exploration of cutting-edge treatment solutions. Headquartered in Japan, Takeda, as a global biopharmaceutical company driven by values and innovation, is committed to fulfilling our promises to patients, employees, and the planet. Our employees across more than 80 countries and regions worldwide share the same mission and uphold the values shaped over two centuries. For more information, please visithttps://www.takeda.com.

Takeda Pharmaceutical entered China in 1994. The headquarters of Takeda China is located in Shanghai, and its main business centers in China are located in cities such as Beijing, Shanghai, Tianjin, Guangzhou, and the Hong Kong Special Administrative Region. The company has offices in major cities across China and currently employs more than 3,000 people in China. With the development of China’s economy and the continuous growth in demand for healthcare, China has become one of Takeda's most important strategic markets globally.

In 2020, Takeda China launched the "Create the Future" five-year strategic plan, continuing to invest heavily in the Chinese market and committing to meet the unmet medical needs in China. By 2025, Takeda China will launch over 15 innovative drugs in China, benefiting more than 10 million Chinese patients. In September 2021, Takeda China's regional headquarters moved to Qiantan, Pudong, Shanghai, marking another new chapter in its development in China. In 2022, Takeda Pharmaceutical Company Limited announced the launch of the "Expand China" strategy, aiming to fully unlock the potential of China as the world’s second-largest pharmaceutical market. By 2030, China will become Takeda's second-largest global market.